Another “String to the Bow” of PJ34, a Potent Poly(ADP-Ribose)Polymerase Inhibitor: An Antiplatelet Effect through P2Y12 Antagonism?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Another “String to the Bow” of PJ34, a Potent Poly(ADP-Ribose)Polymerase Inhibitor: An Antiplatelet Effect through P2Y12 Antagonism?
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 10, Pages e110776
Publisher
Public Library of Science (PLoS)
Online
2014-10-21
DOI
10.1371/journal.pone.0110776
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
- (2013) Joyce S. Balami et al. CNS & Neurological Disorders-Drug Targets
- Prevention of rt-PA induced blood–brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice
- (2013) Fei Teng et al. EXPERIMENTAL NEUROLOGY
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Identification of Pim Kinases as Novel Targets for PJ34 with Confounding Effects in PARP Biology
- (2012) Albert A. Antolín et al. ACS Chemical Biology
- Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
- (2012) Howard S. Kirshner CURRENT PHARMACEUTICAL DESIGN
- Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice
- (2012) Marianne Haddad et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Unusual increase in lumbar network excitability of the rat spinal cord evoked by the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake
- (2012) Sara Ebrahimi Nasrabady et al. NEUROPHARMACOLOGY
- The P2Y12 Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y12/Gi-Dependent Mechanism
- (2012) Binggang Xiang et al. PLoS One
- Platelets at work in primary hemostasis
- (2011) Katleen Broos et al. BLOOD REVIEWS
- New Anti-Thrombotic Drugs for Stroke Prevention
- (2011) Matteo Nicola Dario Di Minno et al. Current Vascular Pharmacology
- The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest
- (2011) Dana L. Madison et al. DNA REPAIR
- Risk and Cumulative Risk of Stroke Recurrence
- (2011) Keerthi M. Mohan et al. STROKE
- Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke
- (2010) Zechariah G. Franks et al. Annals of the New York Academy of Sciences
- Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y 12 Antagonist
- (2010) David Iyú et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase Suppresses Inflammation and Promotes Recovery after Ischemic Injury
- (2009) Tiina M Kauppinen et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Calcium signaling in platelets
- (2009) D. VARGA-SZABO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Limitations of current therapies to prevent thrombosis: a need for novel strategies
- (2009) Jean-Etienne Fabre et al. Molecular BioSystems
- PARP-1 Inhibition Prevents Oxidative and Nitrosative Stress–Induced Endothelial Cell Death via Transactivation of the VEGF Receptor 2
- (2008) Marlene T. Mathews et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment
- (2008) G. Stoll et al. BLOOD
- Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice
- (2008) Marianne Haddad et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
- (2008) Werner Hacke et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now